



## NOTICE

Date: April 3, 2009

Dear Valued Clients:

Foundation Laboratory is pleased to announce that effective April 15, 2009 the FDA approved eSensorR Warfarin Sensitivity Test will be added to our in-house test menu. This test is an *in vitro* diagnostic for the detection and genotyping of the \*2 and \*3 alleles of the cytochrome P450 (CYP450) 2C9 gene locus and the Vitamin K epoxide reductase C1 (VKORC1) gene promoter polymorphism (-1639G>A) from genomic DNA extracted from whole blood samples preserved with EDTA, as an aid in the identification of patients at risk for increased warfarin sensitivity.

### Expected Values/Reference Range

The polymorphisms being genotyped in the eSensorR Warfarin Sensitivity Test are present at the following frequencies in the following ethnic groups in the general U.S. population:

Ethnicity	CYP2C9*2	CYP2C9*3	VKORC1
Caucasian	0.9-20%	0-14.5%	37%
African	0.8-7%	0.4-3%	14%
Asian	0%	0-8.2%	89%

**General Information:** Warfarin (CoumadinR) is the most commonly prescribed anticoagulant in the United States, and is used in the treatment of atrial fibrillation, venous thrombosis, recurrent stroke and pulmonary embolism, and for prevention of clot formation in postsurgical patients, especially after cardiac surgery. However, warfarin exhibits a narrow range of therapeutic concentrations, a wide inter-individual variation in dosage required to reach optimal therapeutic effect, and severe adverse effects of over-dosage, primarily due to bleeding. As a result, the effectiveness of warfarin therapy is typically monitored by frequent measurement of coagulation time.

For supplies and other needs please make sure to contact your Foundation Laboratory representative.

Sincerely;

J. Kermani, MSMT (ASCP, NCA), Ph.D.  
Director of Technical Operations